Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announces cUHDRS subcomponent data from the twelve-month ...
In the first two tasks, people’s minds wandered more when they didn’t have to actively stop a response, and when they had ...
Sydney, Jul 1 (The Conversation) You’re sitting at your desk, writing a short story. You remain focused but after several hours, you still can’t see how to end it. So you go for a run, allowing your ...
Most people think of aging in terms of birthdays. Doctors often consider a person’s age and medical conditions when ...
On June 30th, Skyhawk Therapeutics shared a press release with new twelve-month data from the ongoing Phase 1/2 trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results